NOSA

What NOSA does

NOSA (legal entity NoseOption AB) is a Stockholm-based MedTech company founded in 2011 that designs, manufactures, and sells proprietary intra-nasal plug products under the brands NOZOIL, NOSA smell training, NOSA odor control, NOSA microbial control, and Cerevia. Its consumer portfolio targets individuals seeking improved nasal health, with a clinically proven 8-week smell training kit ($129), 100% natural NOZOIL Original nasal oil ($10.29), microbial control plugs ($8.50, EU only), and odor control plugs ($8.50). Products are manufactured under ISO 13485 medical-device quality certification and developed in collaboration with a leading smell scientist, lending clinical credibility to the offering.

The company monetizes through three revenue streams: direct-to-consumer e-commerce at nosaplugs.com (free shipping above $30), a B2B/professional portal supplying healthcare providers and businesses, and a distributor network with a formal "Become a distributor" program. Geographic reach is concentrated in Europe, with the storefront available in five languages (EN, SV, ES, DE, FR) and US positioning via the nosamed.com domain. Operations are small-scale (1-10 employees disclosed) and the company is privately held with no public listing.

The strategic center of gravity is the Cerevia drug-delivery platform, which uses the proprietary nasal plug to deliver pharmaceutical compounds non-invasively. On July 11, 2025, NOSA announced in vivo study results showing Memantin (an NMDA receptor antagonist relevant to Alzheimer's) achieved plasma absorption up to 8x higher than initially expected at half the recommended dose, providing proof-of-concept ahead of an explicit push to secure collaboration or licensing agreements with pharmaceutical companies before 2026. Cerevia licensing represents the principal upside lever beyond the small consumer-products base.

Name

NOSA

Legal name

NoseOption AB

Website

https://nosamed.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

1–10 employees

Short description

NOSA (NoseOption AB) is a Stockholm-based MedTech company that develops and sells intra-nasal plug products for smell training, odor protection, microbial control, and a pharmaceutical drug-delivery platform, serving consumers across Europe and pursuing licensing deals with pharmaceutical companies.

Ownership category

akta.pro rank

Product category

Nasal Care Medical Devices

NAICS

Toilet Preparation Manufacturing (32562), Toilet Preparation Manufacturing (325620)

SIC

Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834)

akta.pro primary industry

Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK)

akta.pro secondary industry

Respiratory & Allergy Pharmaceuticals (HLAIAAAH)

Keywords

• Nasal care products
• Smell training kits
• Intranasal drug delivery
• Nasal plug medical devices
• Nasal oil moisturizers

Headquarters

HQ city

Stockholm

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Consumer Product Sales (B2C): Direct-to-consumer sales of nasal plugs and related products through the company's e-commerce platform. Products include smell training kits, odor control plugs, microbial control plugs, and NOZOIL nasal oil. Revenue is one-time for individual products.
2. B2B/Professional Sales: Sales to healthcare professionals, distributors, and businesses through the B2B portal. Includes odor control and microbial control products for professional use.
3. Technology Licensing: The company is seeking to license its proprietary drug delivery technology to pharmaceutical companies. The in vivo study proof-of-concept strengthens position for collaboration agreements before 2026.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

NOSA develops, manufactures, and sells intra-nasal plug products including NOSA Smell Training kits, NOSA Microbial Control plugs, NOSA Odor Control plugs, and NOZOIL natural nasal oil for consumer and professional use. The company also operates a proprietary nasal plug drug delivery platform (Cerevia), targeting pharmaceutical licensing partnerships, with proof-of-concept demonstrated in vivo for NMDA receptor antagonists.

Product overview

NOSA (NoseOption AB) offers a portfolio of nasal plug products for consumer and B2B use. The consumer lineup includes NOSA Smell Training ($129), NOSA Microbial Control ($8.50), NOSA Odor Control, and NOZOIL Original ($10.29). The B2B section expands into pharmaceutical applications via Cerevia Drug Delivery, leveraging proprietary nasal plug technology for drug delivery with proof-of-concept demonstrated for neurological treatments. The company is headquartered in Stockholm, Sweden.

Differentiator

Problem solved

Functional benefit

Brands

• NOZOIL: 100% natural nasal oil product for nasal care
• NOSA smell training
• NOSA odor control
• NOSA microbial control
• DRUG DELIVERY (Cerevia)

Products and services

• NOSA Smell Training A clinically proven 8-week smell training program using scented nasal plugs paired with an interactive app, designed to help individuals recover their sense of smell and improve quality of life. Priced at $129 per kit.
• NOSA Microbial Control Nasal plugs in 7-pack format designed to reduce exposure to viruses and bacteria. Available to consumers within the EU at $8.50 per unit. Also offered in a B2B variant for professional use.
• NOSA Odor Control Discreet odor protection nasal plugs designed for use in smelly situations, sold both to consumers and through the B2B/professional portal for healthcare and workplace applications. Priced at $8.50 per unit on the consumer side.
• NOZOIL Original A 100% natural nasal oil product designed for nasal care and moisturization. Sold direct to consumers at $10.29 per unit, with availability restrictions in some countries.
• Cerevia Drug Delivery Platform A pharmaceutical drug delivery solution using NOSA's proprietary nasal plug technology, with proof-of-concept demonstrated in vivo for delivery of NMDA receptor antagonists such as Memantin. Offered for licensing/collaboration with pharmaceutical companies prior to 2026.

Quantifiable outcome

• Drug absorption up to 8x higher than initially expected in in vivo study
• +2 more outcomes

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• OptiNose: US-based specialty pharma focused on nasal drug delivery, with XHANCE (fluticasone) approved for chronic rhinosinusitis. Direct comparison to NOSA's nasal plug drug delivery platform given overlapping focus on nasal drug delivery and partner-driven commercialization.
• Aptar Pharma: Global leader in drug delivery device manufacturing, including nasal spray pumps and inhalation systems. Comparable to NOSA as a drug delivery platform provider serving pharma partners.
• Impel NeuroPharma: Develops intranasal drug delivery using the POD technology for CNS therapies (Trudhesa for migraine). Directly comparable to NOSA in pursuing nasal delivery of systemic-acting drugs for neurological indications.
• NeilMed Pharmaceuticals: Leading OTC brand for nasal saline irrigation and nasal care products. Closest competitor to NOSA's consumer nasal care line (NOZOIL, microbial control) in terms of channel, customer, and category.

Broad incumbents

• Haleon (formerly GSK Consumer Healthcare): Owns Flonase and other major OTC nasal/allergy brands. Comparable as a large incumbent in the OTC nasal care space where NOSA sells its consumer products.
• Church & Dwight: Owns NasalCrom and other OTC nasal allergy products. Comparable as a broader CPG incumbent competing for shelf space and consumer mind-share in nasal care.
• Vectura Group: Specialist inhaled and nasal drug delivery company acquired by Philip Morris. Comparable to NOSA as a nasal/inhaled drug delivery platform targeting pharma licensing.
• Bayer Consumer Health: Markets OTC nasal and respiratory products (Claritin, etc.). Comparable as a large incumbent with established pharma distribution and consumer brand capabilities in nasal/respiratory care.
• Bausch Health: Pharma company with nasal spray product lines (e.g., prescription and OTC nasal steroids). Comparable as a broad pharmaceutical incumbent with nasal product offerings.

Emerging players

• SipNose: Israel-based emerging company developing targeted intranasal drug delivery for CNS indications. Comparable to NOSA as a smaller, earlier-stage peer in the nasal drug delivery platform space.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/nosaplugs
• LinkedInlinkedin.com/company/safety-cloud
• Instagraminstagram.com/nosa_plugs

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NOSA